Dr Christos Mikropoulos

Dr Christos Mikropoulos
MBBS, MSc, MD (Res), MRCP, FRCR, Clinical oncologist

Languages spoken


Expert in

Gastrointestinal cancer, genitourinary cancer, urological cancers


Christos Mikropoulos is a Consultant Clinical Oncologist specialising in the treatment of colorectal and  urological cancers including prostate, bladder, and testicular. He is trained in advanced techniques for radiotherapy including MR Linac, SABR and Brachytherapy. His research interests include cancer genetics and bio markers. Currently a Clinical Oncology Consultant at the Royal Surrey (St Luke's Unit) where he also treats Haematological Malignancies with Radiotherapy and Stereotactic Radiotherapy for Oligometastatic Disease.


  • Trained in Clinical Oncology at the Royal Marsden, Guy's and St Thomas's and Kent Oncology Centre. 
  • Completed MRCP in 2008
  • Merit MSc in Oncology in 2007
  • Completed FRCR in 2013
  • Completed MD (research) in Cancer Genetics at the ICR in 2015

Career positions

Current position(s)
  • Clinical oncologist, Royal Surrey County Hospital


  • Master of Science, Newcastle University, Newcastle
  • MD (Research), University of London, Institute of Cancer Research (ICR)

Expertise and interests

  • Prostate cancer; Bladder cancer; Testicular Cancer; Prostate Brachytherapy; Colorectal Cancer; MR Linac; Stereotactic Radiotherapy

Professional associations

  • Member of the Royal College of Physicians (MRCP)
  • Fellow of the Royal College of Radiologists (FRCP)
  • Member of the European Society of Medical Oncology (ESMO)
  • Member of the European Society of Therapeutic Radiation Oncology (ESTRO)


Awards recieved

  • Merit Award GU ASCO 2014 for Poster Presentation on ‘PROFILE: Results of a pilot study on targeted prostate cancer screen for men with family history of prostate cancer’.
  • 2014 Ross RCR Poster Award for ‘The prevalence of the HOXB13 mutation in UK men and correlation with phenotype and outcomes’.
  • Merit Award GU ASCO 2015 for the Poster Presentation on ‘The IMPACT study: Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in men at higher genetic risk and controls: Prostate-Specific Antigen Velocity as a predictive biomarker in a prospective Prostate Cancer Screening Study of Men with genetic predisposition.’


  • Co-investigator and developer of the GENPROS study, which is a non-interventional study that will collect clinical outcome data for men diagnosed with prostate cancer with a known germline genetic predisposition.
  • Co-investigator and developer of the GENPET study, which is an imaging single arm study assessing the sensitivity of F-Choline-PET to detect nodal metastases in men with a germline BRCA mutation.
  • Co-investigator and developer of the BARCODE-1 study – a prostate cancer screening study which will genetically profile 5000 men and identify the top 10% men at most genetic risk and offer them a diagnostic prostatic biopsy.